Cardiol Therapeutics President and CEO, David Elsley NEW YORK, December 18, 2024 - PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company...